May your protocols stay cost-effective, your peptides stay potent, and your results stay worth every dollar.
F., Mnnich, M., Czirr, E., Hollemann, T
Among these newer treatments, Mounjaro and Semaglutide have garnered attention for their effectiveness in promoting weight loss
In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
CJC-1295 is a GHRH analog that promotes sustained, physiologic growth hormone pulses from the pituitary